Crossmark

New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity

Crossref DOI link: https://doi.org/10.1038/s41416-025-03089-z

Published Online: 2025-06-30

Published Print: 2025-09-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pan, Banglun

Chen, Siyan

Zhang, Zhu

Ye, Dongjie

Zhang, Xiaoxia

Yao, Yuxin

Luo, Yue

Wu, Hao

Wang, Xiaoqian

Tang, Nanhong https://orcid.org/0000-0001-7495-5254
License Information

Text and Data Mining valid from 2025-06-30

Version of Record valid from 2025-06-30
More Information

Article History

Received: 1 August 2024

Revised: 24 May 2025

Accepted: 9 June 2025

First Online: 30 June 2025

Competing interests

: The authors declare no competing interests.

: The study involving patients was approved by the Ethics Committee of Fujian Medical University Union Hospital (approval number [2023]173) and performed in accordance with the Helsinki Declaration and government policies. The animal experiments in this study were approved by the Experimental Animal Ethics Committee of Fujian Medical University (approval number IACUC FJMU 2025-0030) and were carried out according to the Institutional Animal Care and Use Committee guidelines.

Document is current

Any future updates will be listed below